Inmagene Biopharmaceuticals

About:

Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases.

Website: http://www.inmagenebio.com/

Top Investors: TMT Investments, Highlight Capital, Vertex Ventures China, Panacea Venture, VMS Asset Management

Description:

Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldwide by harnessing the most effective resources and efficient processes for drug development. We may take the brainchild of a scientist in one country to conduct proof of concept studies in another, and seamlessly transition to later clinical development globally. We coined our approach “Borderless Innovation.” Focused on immunology and inflammation, we are developing a new generation of drug candidates characterized by prolonged pharmacokinetic and pharmacodynamic effects as well as improved safety margins. This will potentially enable improved efficacy/safety profiles and dosing convenience. Leveraging cutting-edge technology, we have a rich pipeline consisting of four clinical-stage assets, targeting validated pathways, and multiple innovative preclinical candidates.